Lauren Young, MBBS. D Czarnecki, FACD.
The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis
Article first published online: 6 JAN 2012
© 2012 The Authors. Australasian Journal of Dermatology © 2012 The Australasian College of Dermatologists
Australasian Journal of Dermatology
Volume 53, Issue 1, pages 57–60, February 2012
How to Cite
Young, L. and Czarnecki, D. (2012), The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australasian Journal of Dermatology, 53: 57–60. doi: 10.1111/j.1440-0960.2011.00853.x
- Issue published online: 6 FEB 2012
- Article first published online: 6 JAN 2012
- Submitted 28 July 2011; accepted 30 October 2011.
- biological agent;
- cutaneous malignancy;
- squamous cell carcinoma;
We report the cases of two patients who developed eruptive cutaneous squamous cell carcinomas (SCC) soon after commencement of ustekinumab, as treatment of moderate to severe plaque type psoriasis. Ustekinumab is a human monoclonal antibody with a novel mechanism, selectively targeting the shared p40 subunit of interleukin-12 (IL-12) and IL-23. Its efficacy has been well documented in three large phase-III trials (PHOENIX I, PHEONIX 2, ACCEPT). Safety data on this new biological agent continue to grow. To date, no link between ustekinumab and cutaneous carcinogenesis has been demonstrated and, to our knowledge, these cases are the first of their kind. Importantly, both these patients had independent risk factors for developing non-melanoma skin cancers; however, the specific time correlation with the administration of ustekinumab is of note. Our report suggests that ustekinumab may allow the development of cutaneous carcinomata in predisposed individuals.